The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of sequential use of everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with bevacizumab (BEV) with or without interferon (INF) therapy: Overall survival (OS) result from the European AVATOR retrospective study.
Antoine Thiery-Vuillemin
Research Funding - Novartis; Pfizer
Expert Testimony - Novartis; Pfizer
Other Remuneration - Bayer; Novartis; Pfizer; Roche
Christine Theodore
No relevant relationships to disclose
Lutz Jacobasch
No relevant relationships to disclose
Jorg Schmitz
No relevant relationships to disclose
Aline Guillot
Research Funding - Novartis
Other Remuneration - Novartis
Christos Papandreou
No relevant relationships to disclose
Christos E. Emmanouilides
Research Funding - Novartis
Stefano Chong Hun Kim
No relevant relationships to disclose
Meryem Ktiouet
Employment or Leadership Position - Novartis
Nadia Kelkouli
Employment or Leadership Position - Novartis
Thierry Nguyen
Honoraria - Novartis